:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Mohamed, Maha M
Mounjaro and Zepbound remain the core growth engine, while Foundayo turns the Novo competition into a new oral GLP-1 battle
La compaa report un crecimiento vertiginoso del 56% en los ingresos durante el primer trimestre de 2026 y elev su previsin de ingresos en 2 mil millones de dlares para el ao.
However, interventions targeting cardiac remodeling reversal have demonstrated less favorable efficacy results than cardiac regeneration therapies have, with a higher proportion of negative or mixed primary endpoints in clinical trials
US$ 21.24
US$ 22.83
US$ 24.62
US$ 28.34
US$ 26.20
US$ 27.00
US$ 24.17
US$ 27.14
